Alyssum Therapeutics is thrilled to announce that it has successfully raised $26 million in a recent funding round, positioning the company to accelerate its groundbreaking work in the field of immunotherapy. Specializing in the development of next-generation treatments designed to modulate B cells, Alyssum Therapeutics is on the forefront of advancements in therapeutics that could change the landscape of autoimmune diseases and various cancers. This strategic funding will enable the company to expand its research initiatives and propel multiple candidates through the pipeline toward clinical trials. Investors in this latest round include a mix of established biotechnology funds and angel investors who share Alyssum’s vision of harnessing the body’s immune system to fight disease more effectively. With this infusion of capital, Alyssum Therapeutics plans to enhance its proprietary technology platform, which leverages innovative approaches to precisely target and regulate B cell activity. As the demand for advanced and effective therapies continues to rise, Alyssum Therapeutics is committed to leading the charge in the immunotherapy space. The enthusiasm and support from investors not only validate the company’s unique approach but also empower it to bring hope to patients worldwide who are seeking alternatives to traditional treatment methods. By focusing on B cell modulation, Alyssum aims to develop therapies that not only improve patient outcomes but also offer the promise of fewer side effects, ultimately paving the way for a new generation of immunological treatments.
Breaking News: Alyssum Therapeutics Secures $26 Million in Series A Funding for Groundbreaking Immunotherapy Innovations
Recently funded · $26.0M Series aBiotechnology
Get the full Alyssum Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
